Indications for Our Technology

There are more than 1.5 million meniscus tears each year, resulting in 800,000 meniscectomy surgeries in the United States. Currently the treatment options for pain after meniscectomy are limited to replacement with allograft (cadaver) tissue, bone realignment surgeries and knee replacement surgery; there is no FDA-approved product for replacement of the meniscus.

Meniscofix ™, NovoPedic's first product, uses a biodegradable polymer fiber-reinforced scaffold that restores mobility to patients suffering from severe meniscus knee injuries and can prevent the long-term development of arthritis. It is an innovative way to repair these tears and may also eliminate the development of arthritis that is often a complication of current meniscus repair surgery.

Meniscofix has a unique fiber-reinforced design similar to the native meniscus and can be attached to either soft tissue or bone, allowing it to be used in either partial or total meniscus replacement surgery.

Meniscofix has already shown strong results through in vivo proof-of-concept studies. These pre-clinical studies were largely funded by the Department of Defense's "Armed Forces Institute of Regenerative Medicine (AFIRM)" because meniscus injuries are common not only in athletes and laborers but also in the military.